Pharmaceuticals company Strides Pharma Science announced Q3FY25 results Revenue at Rs 11,537 million, grew 14.6% YoY. Gross margin at Rs 6,735 million, grew 25.1% YoY. EBITDA grew 46.9% YoY to Rs 2,103 million with EBITDA margin at 18.2%, grew 401bps YoY. US revenue at USD 73 million, grew 13.7% YoY. Q3FY25 Reported PAT at Rs 900 million. Reported EPS at Rs 9.56. Arun Kumar, Founder & Executive Chairperson, and Badree Komandur, MD & Group CEO, said: “We are pleased to report strong YTD results showcasing a YoY improvement across all key metrics of growth, profitability and efficiency. Our 9MFY25 revenue increased by 17.3% YoY and EBITDA grew by 43.3% YoY despite the demerger of high margin Softgel business. For 9MFY25, the US business recorded a revenue of USD 214 million, a growth of 21.3% YoY, and is well on track to achieve the FY25 outlook of USD 275 million -USD 290 million, post-demerger. Additionally, we are proud to have debuted with an outstanding ESG rating of 76/100 in the S&P; Global’s CSA, 2024. We are placed significantly ahead of our peers in the first year of ESG evaluation, underscoring our unwavering commitment to sustainability and the strength of our processes and governance. Looking ahead, we remain focused on executing our strategies to deliver superior business outcomes and drive long-term value for our stakeholders.” Result PDF